



Brazil

December 23, 2020

Dear Participant,

Thank you for your time and engagement with the COVAX Facility.

You will recall that we presented you with Purchase Opportunities (Window 1) for AstraZeneca, Pfizer, and Sanofi-GSK vaccines. Thank you for your response to these Opportunities.

Further to Friday's announcement of a legally binding agreement with AstraZeneca, today December 23, 2020 marks the opening of Window 2 for AstraZeneca's ChAdOx1-S vaccine. This window will stay open until close **January 22, 2021**.

As part of this deal, the pro rata share of doses for Brazil is 14,241,600 doses, rounded to a full shipping container. The purchase value for this quantity of doses should not exceed US\$ 56,966,400.

To inform your decision-making, please find attached an information fact-pack with additional technical, clinical, regulatory, and commercial details for the AstraZeneca candidate. We intend to release further information on supply terms in early January.

If you wish to opt-out of purchasing doses of AstraZeneca's ChAdOx1-S, please notify the COVAX Facility, using Schedule 3 (see attached "Form of Non-Exercise Notice") of the Commitment Agreement. If you decide to opt out of this candidate during the second window, your government will not be committed to purchase its allocation. An upfront payment to AstraZeneca was not required, and therefore in this case the decision to opt-out does not affect your upfront payment to Gavi.

If you wish to participate in this deal, no communication to Gavi is necessary.

If you wish to opt out, please send a signed Schedule 3 Form to covax@gavi.org by close **January 22, 2021**.

We have not at this stage reached a legally binding agreement with Pfizer or Sanofi-GSK and are not therefore proceeding to the Purchase Option (window 2) stage for these vaccines.

You will also have seen that we have reached an agreement in principle with Johnson & Johnson – a Purchase Opportunity (Window 1) will be presented for this vaccine in early 2021.

Please do not hesitate to let us know if you have any questions.

Sincerely,

A blue ink signature, appearing to be "MS", written in a cursive style.

Marie-Ange Saraka Yao
Managing Director
Resource Mobilisation, Private Sector Partnerships and Innovative Finance